OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of ...
GEN26m
Fragile X Phenotypes Reversed in Mice by Targeting NMDA Receptors
MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.
What is a model organism? Moving beyond E. coli
The non-descript, pill-shaped cell is why we understand fundamental life processes (think DNA replication and transcription).
New mRNA vaccine tested in mice has potential to help fight tuberculosis
A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...
MIT Neuroscientists Discover a Tiny Brain Receptor That Could Transform Fragile X Treatment
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...